AI 聊天
Loading data for ICCC — first visit, this takes a few seconds.

ImmuCell Corporation

ICCC · NasdaqCM · USD

9.85 -0.06 (-0.61%)

收盤價: Sep 11, 2026, 8:00 PM

9.85 +0.00%

盤後: 7:30 PM

市值
$89.46M
下次財報日期
Nov 12, 2026

ImmuCell Corporation(ICCC)股價、分析與資料

內在價值

正在載入內在價值…

分析師預測

股票預測 →

分析師預測無法取得

12個月目標價 · n/a 位分析師

分析師共識: n/a

間隔:1D
正在載入K線和訊號…

財務表現

查看財務 →
營收 (ttm)
$30.68M

正在載入...

最新財報

已通報較預期YoY 變更
營收$7.19Mn/a+11.50%
EPS$0,03+$0,07n/a

下次財報

盤中。

估計 · 升級 →

查看財報詳情 →

指標

買價
7.13
市值
89.5M
淨利(ttm)
787K
0.55
0.07
140.71
-89.55
P/B (ttm)
2.85
P/S (ttm)
2.92
財報日期
Nov 12, 2026
賣價
9.9
成交量
8,102
20 日平均成交量
28,617
開盤價
9.63
前收盤價
9.91
當日區間
9.63 - 9.82
52 週範圍
4.52 - 12.10
股利
n/a
除息日
n/a

關於 ImmuCell Corporation

查看公司資料 →
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is based in Portland, Maine. Biotechnology · Healthcare

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is based in Portland, Maine.

類股 Healthcare
IPO 日期 May 5, 1987
員工 73
證券交易所 NasdaqCM
股票代號 ICCC